This Article Full Text Full Text (PDF) All Versions of this Article: 144/8/3433    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Cheng, W.-S. Articles by Essand, M. Search for Related Content PubMed PubMed Citation Articles by Cheng, W.-S. Articles by Essand, M.

Characterization of the Androgen-Regulated Prostate-Specific T Cell Receptor -Chain Alternate Reading Frame Protein (TARP) Promoter

Clinical Immunology (W.-S.C., V.G., M.E.), Rudbeck Laboratory, Uppsala University, SE-75185 Uppsala, Sweden; and Laboratory of Molecular Biology (I.P.), National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892

Address all correspondence and requests for reprints to: Magnus Essand, Clinical Immunology, Rudbeck Laboratory, Uppsala University, SE-75185 Uppsala, Sweden. E-mail: magnus.essand{at}klinimm.uu.se.

TARP (T cell receptor -chain alternate reading frame protein) is uniquely expressed in males in prostate epithelial cells and prostate cancer cells. Here we demonstrate that TARP expression is regulated by testosterone at the transcriptional level through specific binding of androgen receptor to an androgen response element in the proximal TARP promoter. We further demonstrate that the promoter specifically initiates reporter gene expression in TARP-positive prostate cancer cell lines. To develop a regulatory sequence for prostate-specific gene expression, we constructed a chimeric sequence consisting of the TARP promoter and the prostate-specific antigen (PSA) enhancer. We found that in the prostatic adenocarcinoma cell line LNCaP, the transcriptional activity of the regulatory sequence consisting of a TARP promoter and PSA enhancer is 20 times higher than the activity of a regulatory sequence consisting of the PSA promoter and PSA enhancer. Thus, our studies define a regulatory sequence that may be used to restrict expression of therapeutic genes to prostate cancer cells and may therefore play a role in prostate cancer gene therapy.